Century Therapeutics Net Worth
Century Therapeutics Net Worth Breakdown | IPSC |
Century Therapeutics Net Worth Analysis
Century Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Century Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Century Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Century Therapeutics' net worth analysis. One common approach is to calculate Century Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Century Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Century Therapeutics' net worth. This approach calculates the present value of Century Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Century Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Century Therapeutics' net worth. This involves comparing Century Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Century Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Century Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Century Therapeutics' net worth research are outlined below:
| Century Therapeutics generated a negative expected return over the last 90 days | |
| Century Therapeutics may become a speculative penny stock | |
| Century Therapeutics has high historical volatility and very poor performance | |
| Century Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.23 M. Net Loss for the year was (136.67 M) with profit before overhead, payroll, taxes, and interest of 5.2 M. | |
| Century Therapeutics currently holds about 378.76 M in cash with (88.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.43, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Century Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Syncona Portfolio Ltds Strategic Acquisition of Autolus Therapeutics PLC Shares |
Century Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Century Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Century Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Century Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Century Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Century Therapeutics backward and forwards among themselves. Century Therapeutics' institutional investor refers to the entity that pools money to purchase Century Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 935.6 K | Tang Capital Management Llc | 2024-06-30 | 900 K | Baker Bros Advisors Lp | 2024-09-30 | 797.5 K | State Street Corp | 2024-06-30 | 779.6 K | Renaissance Technologies Corp | 2024-09-30 | 488.2 K | Morgan Stanley - Brokerage Accounts | 457.2 K | Millennium Management Llc | 2024-06-30 | 378.6 K | Charles Schwab Investment Management Inc | 2024-09-30 | 355.3 K | Northern Trust Corp | 2024-09-30 | 352.5 K | Bain Capital Life Sciences Investors, Llc | 2024-06-30 | 5.4 M | Vr Adviser, Llc | 2024-06-30 | 5.4 M |
Follow Century Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 105.44 M.Market Cap |
|
Project Century Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.74) | (0.70) |
When accessing Century Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Century Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Century Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Century Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Century Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Century Therapeutics' management manipulating its earnings.
Evaluate Century Therapeutics' management efficiency
Century Therapeutics has return on total asset (ROA) of (0.209) % which means that it has lost $0.209 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6261) %, meaning that it created substantial loss on money invested by shareholders. Century Therapeutics' management efficiency ratios could be used to measure how well Century Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Century Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 195.3 M, whereas Total Assets are forecasted to decline to about 352.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.11 | 1.91 | |
| Tangible Book Value Per Share | 3.11 | 1.88 | |
| Enterprise Value Over EBITDA | (1.63) | (1.71) | |
| Price Book Value Ratio | 1.07 | 1.12 | |
| Enterprise Value Multiple | (1.63) | (1.71) | |
| Price Fair Value | 1.07 | 1.12 | |
| Enterprise Value | 197.8 M | 187.9 M |
Leadership at Century Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 1.9555 | Revenue 2.7 M | Quarterly Revenue Growth 4.345 | Revenue Per Share 0.037 | Return On Equity (0.63) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Century Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Century Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Century Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Century Therapeutics time-series forecasting models is one of many Century Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Century Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Century Therapeutics Earnings per Share Projection vs Actual
Century Therapeutics Corporate Management
| Michael Diem | Chief Officer | Profile | |
| Morgan Conn | Chief Officer | Profile | |
| Michael Naso | Senior Engineering | Profile | |
| Nick MD | Senior Development | Profile | |
| Kenneth JD | Head Compliance | Profile | |
| Chad Cowan | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share 0.037 | Quarterly Revenue Growth 4.345 | Return On Assets (0.21) | Return On Equity (0.63) |
The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.